Search

Your search keyword '"van Melick, H."' showing total 3 results
Start Over Author "van Melick, H." Publisher elsevier
3 results on '"van Melick, H."'

1. Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”

Author

MS Urologische Oncologie, Cancer, Urologie Medisch volwassenen, Grimm, Marc Oliver, van der Heijden, A. G., Colombel, Marc, Muilwijk, Tim, Martínez-Piñeiro, Luis, Babjuk, Marko M., Türkeri, Levent N., Palou, Joan, Patel, Anup, Bjartell, Anders S., Caris, Christien, Schipper, Raymond G., Witjes, Wim P.J., Horstmann, Jörg, Machtens, Stefan, Mumperow, Eberhard, Ghazal, Andreas Al, Pulte, Thomas, Stephan-Odenthal, Michael, Gakis, Georgios, Kramer, Mario, Zaak, Dirk, Schmitz-Dräger, Bernd, Schreier, Holger, Lehmann, Jan, Werner, Torsten, Klier, Jörg, Marin, Jan, Rulf, Wolfgang, Hellmis, Eva, Schneider, Andreas, Spiegelhalder, Wirth, Manfred, Klotz, Theodor, Suttmann, Henrik, Siebels, Michael, Rodemer, Gerd, Rudolph, Robert, Zillmann, Roger, de Bruin, M., Bos, S., van Moorselaar, R., de Reijke, T., Boormans, J., Wijsman, B., van Melick, H. H.E., van Boven, E., Meijer, R. P., Vergunst, H., te Slaa, E., Leliveld-Kors, A. M., Ruffion, Alain, Pfister, Christian, Roupret, Morgan, Irani, Jacques, Stoica, Gabriel, Van Bruwaene, Siska, Ameye, Filip, Arentsen, Harm, Joniau, Steven, Beardo, Pastora, MS Urologische Oncologie, Cancer, Urologie Medisch volwassenen, Grimm, Marc Oliver, van der Heijden, A. G., Colombel, Marc, Muilwijk, Tim, Martínez-Piñeiro, Luis, Babjuk, Marko M., Türkeri, Levent N., Palou, Joan, Patel, Anup, Bjartell, Anders S., Caris, Christien, Schipper, Raymond G., Witjes, Wim P.J., Horstmann, Jörg, Machtens, Stefan, Mumperow, Eberhard, Ghazal, Andreas Al, Pulte, Thomas, Stephan-Odenthal, Michael, Gakis, Georgios, Kramer, Mario, Zaak, Dirk, Schmitz-Dräger, Bernd, Schreier, Holger, Lehmann, Jan, Werner, Torsten, Klier, Jörg, Marin, Jan, Rulf, Wolfgang, Hellmis, Eva, Schneider, Andreas, Spiegelhalder, Wirth, Manfred, Klotz, Theodor, Suttmann, Henrik, Siebels, Michael, Rodemer, Gerd, Rudolph, Robert, Zillmann, Roger, de Bruin, M., Bos, S., van Moorselaar, R., de Reijke, T., Boormans, J., Wijsman, B., van Melick, H. H.E., van Boven, E., Meijer, R. P., Vergunst, H., te Slaa, E., Leliveld-Kors, A. M., Ruffion, Alain, Pfister, Christian, Roupret, Morgan, Irani, Jacques, Stoica, Gabriel, Van Bruwaene, Siska, Ameye, Filip, Arentsen, Harm, Joniau, Steven, and Beardo, Pastora

Published
2020

2. Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial

Author

Mulders, Peter F. A., Martinez-Pineiro, Luis, Heidenreich, Axel, Babjuk, Marko, Colombel, Marc, Colombo, Renzo, Radziszewski, Piotr, Korneyev, Igor, Surcel, Cristian, Yakovlevi, Pavel, Witjes, J. Alfred, Caris, Christien, Schipper, Raymond, Witjes, Wim P. J., Villers, A., Malavaud, B., Rouboud, G., Grimm, M. O., Retz, M., Wagenlehner, F., Stenzl, A., Olbert, P., Niegisch, G., Hakenberg, O., Goebell, P., Wirth, M., Bolenz, C., Tubaro, A., Selli, C., Porena, M., Kerst, M., van Melick, H., Antoniewicz, A., Chlosta, P., Palou, J., Ponce Diaz-Reixa, J., Alonso Dorrego, J. M., Llorente, C., Fernandez-Gomez, J., Alvarez Maestro, M., Alvarez-Ossorio, J. L., Sanchez Chapado, M., Ribal, M., Guix, M., Bellmunt, J., Villacampa, F., Schraml, J., Zachoval, R., Sinescu, I, Stoica, L., Sakalo, V, Matveev, V, Alekseev, B., Komyakov, B., Van den Steen, Peter, Mulders, Peter F. A., Martinez-Pineiro, Luis, Heidenreich, Axel, Babjuk, Marko, Colombel, Marc, Colombo, Renzo, Radziszewski, Piotr, Korneyev, Igor, Surcel, Cristian, Yakovlevi, Pavel, Witjes, J. Alfred, Caris, Christien, Schipper, Raymond, Witjes, Wim P. J., Villers, A., Malavaud, B., Rouboud, G., Grimm, M. O., Retz, M., Wagenlehner, F., Stenzl, A., Olbert, P., Niegisch, G., Hakenberg, O., Goebell, P., Wirth, M., Bolenz, C., Tubaro, A., Selli, C., Porena, M., Kerst, M., van Melick, H., Antoniewicz, A., Chlosta, P., Palou, J., Ponce Diaz-Reixa, J., Alonso Dorrego, J. M., Llorente, C., Fernandez-Gomez, J., Alvarez Maestro, M., Alvarez-Ossorio, J. L., Sanchez Chapado, M., Ribal, M., Guix, M., Bellmunt, J., Villacampa, F., Schraml, J., Zachoval, R., Sinescu, I, Stoica, L., Sakalo, V, Matveev, V, Alekseev, B., Komyakov, B., and Van den Steen, Peter

Published
2019

3. Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.

Author

Beije N, de Kruijff IE, de Jong JJ, Klaver SO, de Vries P, Jacobs RAL, Somford DM, Te Slaa E, van der Heijden AG, Alfred Witjes J, Fossion LMCL, Boevé ER, van der Hoeven J, van Melick HHE, Wijburg CJ, Bickerstaffe H, Martens JWM, de Wit R, Kraan J, Sleijfer S, and Boormans JL

Subjects
Aged, Female, Humans, Male, Muscles pathology, Neoadjuvant Therapy, Recurrence, Neoplastic Cells, Circulating, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
Abstract

Background: Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic muscle-invasive bladder cancer (MIBC). NAC is, however, underutilized in practice because of its associated limited overall survival (OS) benefit and significant treatment-related toxicity. We hypothesized that the absence of circulating tumour cells (CTCs) identifies MIBC patients with such a favourable prognosis that NAC may be withheld., Patients and Methods: The CirGuidance study was an open-label, multicentre trial that included patients with clinical stage T2-T4aN0-N1M0 MIBC, scheduled for radical cystectomy. CTC-negative patients (no CTCs detectable using the CELLSEARCH system) underwent radical surgery without NAC; CTC-positive patients (≥1 detectable CTCs) were advised to receive NAC, followed by radical surgery. The primary endpoint was the 2-year OS in the CTC-negative group with a prespecified criterion for trial success of ≥75% (95% confidence interval (CI) ±5%)., Results: A total of 273 patients were enrolled. Median age was 69 years; median follow-up was 36 months. The primary endpoint of 2-year OS in the CTC-negative group was 69.5% (N = 203; 95% CI 62.6%-75.5%). Two-year OS was 58.2% in the CTC-positive group (N = 70; 95% CI 45.5%-68.9%). CTC-positive patients had a higher rate of cancer-related mortality [hazard ratio (HR) 1.61, 95% CI 1.05-2.45, P = 0.03] and disease relapse (HR 1.87, 95% CI 1.28-2.73, P = 0.001) than CTC-negative patients. Explorative analyses suggested that CTC-positive patients who had received NAC (n = 22) survived longer than CTC-positive patients who had not (n = 48)., Conclusion: The absence of CTCs in MIBC patients was associated with improved cancer-related mortality and a lower risk of disease relapse after cystectomy; however, their absence alone does not justify to withhold NAC. Exploratory analyses suggested that CTC-positive MIBC patients might derive more benefit from NAC., Trial Registration: Netherlands Trial Register NL3954; https://www.trialregister.nl/trial/3954., Competing Interests: Diclosure JWMM and SS report a research agreement with Menarini, unrelated to the currently submitted manuscript. JLB reports consultancy work for MSD, Janssen, ISMAR Health Care, Eight Medical, BMS and AMBU (all paid to the Erasmus MC) and a research agreement with Decipher. All other authors declare no conflict of interest., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results